DMKPQ (DMK Pharmaceuticals) Ending Cash Position: $6.66 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Ending Cash Position?

DMK Pharmaceuticals DMKPQ -99.00% 16 Ending Cash Position is $6.66 Mil as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

DMK Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2023 was $6.66 Mil.

DMK Pharmaceuticals's quarterly Ending Cash Position declined from Mar. 2023 ($3.13 Mil) to Jun. 2023 ($0.67 Mil) but then increased from Jun. 2023 ($0.67 Mil) to Sep. 2023 ($6.66 Mil).

DMK Pharmaceuticals's annual Ending Cash Position increased from Dec. 2020 ($6.75 Mil) to Dec. 2021 ($23.25 Mil) but then declined from Dec. 2021 ($23.25 Mil) to Dec. 2022 ($1.11 Mil).

DMK Pharmaceuticals Ending Cash Position Related Terms

DMK Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Ending Cash Position Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.27 8.81 6.75 23.25 1.11

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.45 1.11 3.13 0.67 6.66
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

DMK Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.243+-22.132
=1.11

DMK Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.671+5.993
=6.66

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $6.66 Mil mean?
DMK Pharmaceuticals (DMKPQ) has a Ending Cash Position of $6.66 Mil as of Sep. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Ending Cash Position too high?
DMK Pharmaceuticals' current Ending Cash Position is $6.66 Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Ending Cash Position compare to CNNC and THCT?
DMK Pharmaceuticals' Ending Cash Position of $6.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Ending Cash Position is $6.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Ending Cash Position of $6.66 Mil. The current Ending Cash Position is $6.66 Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Ending Cash Position is $6.66 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price